Biogen Idec has entered into a definitive license agreement with Trillium Therapeutics, granting exclusive worldwide rights to one of the company’s immune-based biologics development programmes.

Trillium CEO Dr Niclas Stiernholm said that Biogen Idec is a premier biotechnology partner and a world leader in immunology research and development.

Under the terms of the agreement, Trillium will receive an upfront payment and is eligible to receive milestone payments based on achievements of specified clinical, regulatory and commercial accomplishments. Trillium will also receive royalties on global product sales.

Biogen Idec will then be solely responsible for clinical development, regulatory approvals, manufacturing and commercialisation.